Nicergoline
Nicergoline is an ergot derivative, which is used for the symtomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. Nicergoline is given orally as well as parenterally.
Primary Characteristics
It is of Synthetic origin and belongs to Ergot derovation.
Molecular Weight: 484.4 · pKa: 8.4 · Solubility in Water: > 1 in 10000 · Solubility in Alcohol: > 1 in 10 · Non-proprietary name: Nicergoline.

Pharmacokinetics
Distribution: Nicergoline has a plasma protein binding is 93 - 95 %.
Elimination: it is metabolised via Extensive, plasma half-life is 3.8 hr, renal excretion is 51 %.
Advertisement
Indications
Nicergoline is primarily indicated in conditions like Mental sequelae of cerebrovascular disorder, Pruritus.
Contraindications
Nicergoline is contraindicated in conditions like Myocardial infarction, Bradycardia.
Dosage
Nicergoline's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 3 mg | 3 mg | — | IM | Twice daily. |
| 6 mg | 6 mg | — | IV | Daily (Infusion) |
| 7.5 mg | 7.5 mg | Every 8h | PO | |
| 30 drops | 30 drops | Every 8h | PO | |
| 60 mg | 60 mg | — | PO | daily in 2 divided dose |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
The signs and symptoms that are produced after acute overdosage of Nicergoline are Severe hypotension.
Nicergoline is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Anorexia , Constipation , Diarrhea, Dizziness, Drowsiness, Dry mouth, Headache, Malaise, Nausea, Pruritus , Skin RashX, Tinnitus, Urticaria, Vertigo.
Warnings / Precautions
Available Brands
None recorded.
Storage Conditions
Drug Classification
- 1.12.8 — Other cardiovascular preparations
- 2.24.6 — Cerebrovascular drugs